Table 2. Comparison of Strongyloides testing methodology at baseline, pre-antiretroviral therapy.
| Patient no. | CrAg-ELISA | LIPS | NIE | Stool O&P | Country of origin |
| 1 | + | − | − | − | Ethiopia |
| 2 | + | + | − | Not done | Ethiopia |
| 3 | + | − | − | Not done | Guatemala |
| 4 | + | − | − | − | Ethiopia |
| 5 | + | − | − | − | USA |
| 6 | + | − | − | Not done | USA |
| 7 | + | − | − | Not done | Cameroon |
| 8 | + | − | − | Not done | USA |
| 9 | + | − | − | − | USA |
| 10 | + | − | − | Not done | USA |
| 11 | + | + | − | + | Honduras |
| 12 | + | − | − | Not done | USA |
| 13 | + | + | − | + | Honduras |
| 14 | + | − | − | − | USA |
| 15 | + | − | − | − | Honduras |
| 16 | + | + | − | Not done | Honduras |
| 17 | + | − | − | Not done | USA |
| 18 | − | − | +/− | Not done | El Salvador |
| 19 | − | − | +/− | − | Ethiopia |
| 20 | + | − | + | Not done | Sierra Leone |
| 21 | − | + | − | − | El Salvador |
| 22 | + | − | − | + | Mexico |
| 23 | − | + | − | − | El Salvador |
| 24 | + | − | − | Not done | Uganda |
| 25 | + | − | − | − | Guatemala |
| 26 | + | − | − | Not done | USA |
| 27 | + | + | − | Not done | El Salvador |
| 28 | + | − | − | − | USA |
| 29 | + | − | − | − | Guatemala |
| 30 | + | − | − | − | Ethiopia |
Note: At baseline, pre-ART negative results were seen in all four Strongyloides detection methods in 73 other patients, when tested. Stool studies were sent prospectively for evaluation of diarrhea in select patients, as clinically indicated.
CrAg-ELISA, crude antigen enzyme-linked immunosorbent assay; LIPS, luciferase immunoprecipitation system assay; NIE, recombinant-based immunoassay; stool O&P, stool ova and parasites.